-

InterVenn Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences today announced that it will be participating via webcast in the Morgan Stanley 19th Annual Global Healthcare Conference.

Aldo Carrascoso, CEO is scheduled to participate in a fireside chat on Friday, September 10th, 2021 at 11:45 a.m. ET.

Please follow the link (https://intervenn.com/investors/) to the “Investors” page on the InterVenn website and a live webcast of the event.

About InterVenn Biosciences

InterVenn Biosciences utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.

Contacts

Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@venn.bio

Media contact
Andrea Vuturo
(888) 706-1670
press@venn.bio

InterVenn Biosciences

Details
Headquarters: SOUTH SAN FRANCISCO, California
CEO: Aldo Carrascoso
Employees: 0-100
Organization: PRI

Release Summary
InterVenn Biosciences announces that it will be participating via webcast in the Morgan Stanley 19th Annual Global Healthcare Conference.
Release Versions

Contacts

Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@venn.bio

Media contact
Andrea Vuturo
(888) 706-1670
press@venn.bio

Social Media Profiles
More News From InterVenn Biosciences

InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer

WASHINGTON--(BUSINESS WIRE)--InterVenn presents results at SITC on a predictive signature capable of identifying NSCLC patients that will benefit most from checkpoint inhibitors...

InterVenn Biosciences to Participate at Two Upcoming Investor Conferences in November

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--InterVenn Biosciences announces their participation in investor conferences: Stifel 2021 Healthcare Conference and Canaccord Genuity Virtual Forum....
Back to Newsroom